The patients were determined to be at high risk for type II endoleaks based on pre-procedural assessment and prevailing clinical standards. Persistent type II endoleaks are widely considered a failure of EVAR therapy and a significant driver of late aneurysm sac expansion and reintervention[1]. As a result, sac management and elimination of type II endoleaks remain a major focus of vascular care. Regulatory StatusThe Cygnum™ Aneurysm Sac Management Device is an investigational device and is not approved for sale or commercial use in any geography, including the United States, European Union, New Zealand, or Japan. About Life Seal VascularLife Seal Vascular (www.lifesealvascular.com) is a privately held medical device company dedicated to developing innovative solutions to revolutionize endovascular treatment.

Source: The Herald January 02, 2026 21:20 UTC